Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 5,653,700 new fully paid ordinary shares, with an issue date of March 16, 2026. The issuance of these additional securities expands the company’s quoted share capital, potentially enhancing liquidity in its stock and supporting future corporate or funding initiatives for ongoing operations and growth.
The new shares arise from the exercise or conversion of existing options or other convertible securities, as indicated in the application. This move reflects continued utilisation of equity-based instruments within Paradigm’s capital structure, which may signal stakeholder confidence and provide additional financial flexibility for the company’s biopharmaceutical development programs.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is a biopharmaceutical company listed on the Australian Securities Exchange under the code PAR. The company operates in the life sciences sector, focusing on the development and commercialisation of pharmaceutical products and related therapies for medical markets.
YTD Price Performance: -23.53%
Average Trading Volume: 961,174
Technical Sentiment Signal: Sell
Current Market Cap: A$114.2M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.